Company / R&D Expense
vTv Therapeutics Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$13.6M
FY2025
5-year range
$11.0M / $15.1M
FY2021-FY2025
Trend
+10.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $11M in FY2022 to $45M in FY2018.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of -10.0%.
Improved from $13M to $14M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +7.3%
- 5-Year CAGR
- -10.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.0%, indicating a declining trend.
- In FY2025, r&d expense increased 10.0% year-over-year.
- Peak r&d expense was recorded in FY2018.
- Lowest r&d expense in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.6M | +10.0% |
| FY2024 | $12.4M | -7.3% |
| FY2023 | $13.3M | +21.0% |
| FY2022 | $11.0M | -27.1% |
| FY2021 | $15.1M | -34.4% |
| FY2020 | $23.0M | -41.9% |
| FY2019 | $39.6M | -11.8% |
| FY2018 | $45.0M | +65.0% |
| FY2017 | $27.2M | +56.7% |
| FY2016 | $17.4M | -22.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026